US court delays launch of country's first biosimilar

This article was originally published in SRA

07 May 2015
News

Donna Young @ScripDonnaDC Donna.young@informa.com

Executive Summary

The first biosimilar may have been approved in the US but its launch is being delayed. Amgen has won its motion for an injunction to stop Novartis and its Sandoz unit from launching Zarxio (filgrastim-sndz) – referenced on Amgen's human granulocyte colony-stimulating factor, Neupogen (filgrastim) – until the US Court of Appeals for the Federal Circuit renders a decision in an ongoing lawsuit.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS118213

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS118213

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

US court delays launch of country's first biosimilar

News

Executive Summary

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert